J07BD54 • measles, rubella, urlian, live attenuated vaccine • Antiinfectives for systemic use | Viral vaccines | Measles vaccines
The measles, mumps, and rubella (MMR) live attenuated vaccine is used to prevent three highly contagious viral diseases: measles, rubella, and mumps. The vaccine contains attenuated forms of the viruses that cause these diseases, stimulating the immune system to produce specific antibodies against each of them.
The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for children and adults who have not been previously vaccinated or have not had these diseases.
Common side effects include fever, rashes, pain, or swelling at the injection site. In rare cases, severe adverse reactions such as febrile seizures or allergic reactions may occur.
The MMR vaccine is an essential preventive measure for reducing the incidence of these diseases and their associated complications, such as encephalitis, deafness, or viral pneumonia.
Substance: measles, rubella, urlian, live attenuated vaccine
Date of last drug list: 01-07-2013
Commercial code: W51909004
Concentration: 0.5ml
Pharmaceutical form: powder + solvent for injection suspension
Quantity: 10
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).